BioAtla Investor Presentation Deck

Phase 1 results with BA3021 support advancing into Phase 2 in multiple indications ROR2+ Tumor Types NSCLC Melanoma SCCHN bicatla Results ▪ PR in 2/3 patients who previously experienced failure on PD-1 and who received Ph2 dose or higher CR in 1 / 1 patient who previously experienced failure on PD-1 Clearance of pulmonary metastases followed by normalization of adenopathy ■ Continued CR off treatment for over 2 years . ▪ PR in 1/1 ROR2+ refractory to four prior lines of therapy including cetuximab and PD-1 (pembrolizumab) Promising safety and tolerability profile across multiple tumor types No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is a first-in-class therapy across multiple tumor types BioAtla| Overview 27

View entire presentation